Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct-Dec;7(4):144-148.
doi: 10.4103/2231-4040.191425.

Comparison of the effects of methylphenidate and the combination of methylphenidate and risperidone in preschool children with attention-deficit hyperactivity disorder

Parvin Safavi  1 , Ali Hasanpour Dehkordi  2 , Nasim Ghasemi  3
Affiliations

Comparison of the effects of methylphenidate and the combination of methylphenidate and risperidone in preschool children with attention-deficit hyperactivity disorder

Parvin Safavi et al. J Adv Pharm Technol Res. 2016 Oct-Dec.

Abstract

Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder among preschool children but the number of controlled clinical trials regarding psychopharmacological treatment in this age group is limited. The aim of this study was to compare methylphenidate with the combination of methylphenidate and risperidone in preschool children with ADHD. Forty-two preschool children, aged 3-6 years, diagnosed with ADHD by a child and adolescent psychiatrist according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition-Text Revision criteria, were enrolled in a 6-week, single-blind clinical trial and administered with methylphenidate (5-30 mg/dl) or the combination of methylphenidate and risperidone (0.25-2 mg/dl) in Iran. Treatment outcomes were assessed using the Conners' Rating Scale and Clinical Global Impression (CGI) Scale at baseline and 3 and 6 weeks after starting the drugs administration. Side effects were rated by a checklist and body weight was measured at each visit. There were no significant differences between the two protocols in Parent Conners' Rating Scale scores (P > 0.05) and CGI scores (P > 0.05). Both groups showed a significant improvement in ADHD symptoms over the 6 weeks of treatment for Parent Conners' Rating Scale (P < 0.001). The combination group used significantly lower doses of methylphenidate compared to the other group (P = 0.002). The most common adverse effects were anorexia (21.7%) and daytime drowsiness (17.4%) in combination treatment group and insomnia (33.3%) and anorexia (25%) in methylphenidate group. Risperidone and methylphenidate may be effective and well tolerated in preschool children with ADHD, and adding risperidone to methylphenidate may decrease the occurrence of some side effects of methylphenidate such as insomnia and anorexia and lower the dose of methylphenidate may be needed to control symptoms.

Keywords: Attention-deficit hyperactivity disorder; methylphenidate; preschool children; risperidone.

PubMed Disclaimer

References

    1. Dehkordi AH, Heydarnejad MS. Effect of booklet and combined method on parents' awareness of children with beta-thalassemia major disorder. J Pak Med Assoc. 2008;58:485–7. - PubMed
    1. Solati K, Mousavi M. The efficacy of mindfulness-based cognitive therapy on general health in patients with systemic lupus erythematosus: A randomized controlled trial. J Kerman Univ Med Sci. 2015;22:499–509.
    1. Sadock B, Sadock V, Ruiz P. Comprehensive Text Book of Psychiatry. 9th ed. New York: Lippincott Williams & Wilkins; 2009.
    1. Safavi P, Ganji F, Bidad A. Prevalence of attention-deficit hyperactivity disorder in students and needs modification of mental health services in Shahrekord, Iran in 2013. J Clin Diagn Res. 2016;10:LC25–8. - PMC - PubMed
    1. Safavi P, Hasanpour-Dehkordi A, AmirAhmadi M. Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial. J Adv Pharm Technol Res. 2016;7:43–7. - PMC - PubMed

LinkOut - more resources